Over a million species of animals and plants are now hanging by a thread, more than ever before in human history, says the International Science-Policy Platform on Biodiversity and Ecosystem Services ...

Earth looked much different not just millions, but even decades and centuries ago. Many animal species that once existed are nowhere to be found. From human activity to climate change, new animals ...

From dire wolves to woolly mammoths, the idea of resurrecting extinct species has captured the public imagination. Colossal Biosciences, the Dallas-based biotech company leading the charge, has made ...

Just because a species is presumed extinct doesn’t mean it’s gone forever. Here are four glowing examples of this unique, and felicitous, phenomenon. Not all species that have been classified as ...

Dire wolves were massive and highly intelligent animals nearly the size of a small horse, capable of ripping a man’s arm off as easily as a dog kills a rat. They lived in cold regions in a place ...

Their names are Romulus, Remus and Khaleesi, and they’re the first dire wolves to walk the Earth in over 10,000 years — or so one biotech company and a flurry of recent headlines say. On April 7, ...

Should we bring back extinct animals? Wrong question. Why are we bringing back extinct animals when we have animals, plants, and fungi that are going extinct now, daily? By 2050, up to half of all ...

Texas-based "de-extinction" startup Colossal Laboratories & Biosciences have supposedly revived the long-extinct dire wolf. While excitement builds about the $10 billion startup's news, experts say ...

Kelli Bender is the Pets Editor at PEOPLE. She has been working at PEOPLE since 2013, covering pets, animal rescue and wildlife. Curiosity Stream/YouTube Dire wolves, the canine companions from Game ...

A version of the dodo bird (Raphus cucullatus) could make a return someday soon. Colossal Biosciences announced this week several milestones in its quest to bring the extinct species back to life. On ...

Timothy Hearn does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...